Short summary: A phase 3a trial published in The Lancet found that once-weekly cagrilintide-semaglutide, also known as CagriSema, lowered A1C and body weight when added to basal insulin in adults with type 2 diabetes. The results are promising, but this combination should still be viewed as a trial finding, not a reason for anyone to change insulin or other medicines on their own.
What happened
The REIMAGINE 3 trial studied cagrilintide-semaglutide in adults with type 2 diabetes who were already using once-daily basal insulin, with or without metformin. Participants had A1C levels between 7.0% and 10.5% at the start of the study.
The trial was double-blind, randomized, placebo-controlled, and conducted at 46 centers in six countries. In total, 274 adults were randomly assigned to one of three groups for 40 weeks:
- Cagrilintide 2.4 mg plus semaglutide 2.4 mg once weekly.
- Cagrilintide 1.0 mg plus semaglutide 1.0 mg once weekly.
- Matched placebo added to basal insulin.
Why this matters
Many people with type 2 diabetes eventually need basal insulin, but insulin treatment can be linked with weight gain and low blood sugar concerns. Some people also remain above their A1C target despite basal insulin.
REIMAGINE 3 is important because it looked at a possible future option that combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, an amylin-based medicine under development. The goal was to see whether this once-weekly combination could improve glucose control and weight when used with basal insulin.
What the trial found
At 40 weeks, A1C fell more with cagrilintide-semaglutide than with placebo.
- The 2.4 mg plus 2.4 mg group had a mean A1C reduction of 2.33 percentage points.
- The 1.0 mg plus 1.0 mg group had a mean A1C reduction of 2.10 percentage points.
- The placebo group had a mean A1C reduction of 0.66 percentage points.
Body weight also fell with the active treatment groups. The Lancet abstract reports weight reductions of about 10 to 12% with cagrilintide-semaglutide.
Safety findings
Adverse events were reported in 80% of participants in the higher-dose cagrilintide-semaglutide group, 71% in the lower-dose cagrilintide-semaglutide group, and 71% in the placebo group. Most were mild or moderate gastrointestinal symptoms.
No severe hypoglycemia was reported in the trial. One death occurred in the lower-dose active treatment group and was assessed as not related to treatment.
Important caveats
Cagrilintide-semaglutide is under development and is not currently FDA-approved as a combination product for type 2 diabetes. This article is about trial results, not availability or a prescribing recommendation.
This was a 40-week trial with 274 participants. That is useful evidence, but it is not enough to answer every long-term question about safety, durability, rare side effects, cost, or who would benefit most.
The study was funded by Novo Nordisk, the company developing cagrilintide-semaglutide. That does not make the results invalid, but it is important context for readers.
The results apply to the specific trial population: adults with type 2 diabetes using basal insulin, with or without metformin, and with A1C between 7.0% and 10.5%. The findings may not apply to people using different diabetes regimens or people with different health circumstances.
The 10 to 12% weight reduction was an average result in this trial population, and individual results can vary. The trial also does not settle long-term cardiovascular outcomes or rare side effects.
People using multiple daily insulin injections, insulin pumps, SGLT2 inhibitors, other GLP-1 or GIP-based medicines, or other treatment combinations should not assume the same results apply to them.
Practical takeaway
The main takeaway is that CagriSema may become an important future option for some adults with type 2 diabetes who use basal insulin, but it is not a do-it-yourself treatment decision.
Do not stop, reduce, or change basal insulin because of this news. If you use insulin and are concerned about weight gain, low blood sugar, or A1C that remains above target, discuss approved options with your diabetes team. Medication choices depend on kidney function, heart disease risk, weight goals, hypoglycemia history, side effects, cost, and access.
Evidence and source summary
The source is a peer-reviewed Lancet phase 3a study titled “Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3).” It was published online on July 4, 2026.
- Primary source: PubMed record
- Journal DOI: Lancet DOI page
- Trial record: ClinicalTrials.gov NCT06323161
Suggested categories and tags
Categories: News, Type 2 diabetes, Diabetes Medication, Obesity.
Tags: CagriSema, cagrilintide, semaglutide, basal insulin, REIMAGINE 3, type 2 diabetes, Lancet.